【摘要】 目的探讨中晚期原发性肝癌患者综合治疗后血清甲胎蛋白(AFP)水平与预后的相关性。方法选择57例AFP阳性(AFP>500 ng/ml)的中晚期原发性肝癌患者,综合治疗后定期检测血清AFP,治疗后AFP下降者为A组,治疗后AFP上升者分为B组,(判断治疗后AFP上升或下降的标准以治疗前AFP值差±10%以上)。结果 32例(A组)患者AFP有不同程度的降低,25例(B组)患者AFP有不同程度升高。A组患者的中位生存时间为10.6个月,而B组的中位生存时间为5.1个月,两组差异有统计学意义(P﹤0.01)。结论血清中AFP水平可以作为判断肝癌患者综合治疗后的预后指标。更多还原

【Abstract】 Objective To investigate the relationship between the changes of AFP and prognosis after the comprehensive treatment of advanced primary hepatic carcinoma. Methods Selecting 57 patients of advanced primary hepatic carcinoma with AFP positive status. AFP was determined after the comprehensive treatment. The patients were divided into A、B groups based on the decreasing and increasing of AFP levels. Results There were 32 cases with the decreasing AFP levels( A group) and 25 cases with the increasing AFP levels( B group). The median survival time of A group was 10. 6months and B group was5. 1months with a statistically significant difference( P < 0. 01). Conclusion The levels of serum AFP can be used as indicators for determining the prognosis after the comprehensive treatment of advanced primary hepatic carcinoma.更多还原